In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Folic acid administration has a modest anti-inflammatory effect in apoE deficient mice

Session Poster session 3

Speaker Evangelos Oikonomou

Event : ESC Congress 2015

  • Topic : basic science
  • Sub-topic : Basic Science - Vascular Biology and Physiology
  • Session type : Poster Session

Authors : P Kourkouti (Athens,GR), G Siasos (Athens,GR), A Briasoulis (Athens,GR), A Valatsou (Athens,GR), G Vogiatzi (Athens,GR), C Antoniades (Athens,GR), E Oikonomou (Athens,GR), M Zaromytidou (Athens,GR), D Perrea (Athens,GR), D Tousoulis (Athens,GR)

Authors:
P. Kourkouti1 , G. Siasos1 , A. Briasoulis1 , A. Valatsou1 , G. Vogiatzi1 , C. Antoniades1 , E. Oikonomou1 , M. Zaromytidou1 , D. Perrea1 , D. Tousoulis1 , 1University of Athens Medical School, 1st Cardiology Department, “Hippokration” Hospital - Athens - Greece ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 436

Background: Supplementation with folic acid (FA) has been proposed as a means to suspend atherosclerosis progression in subjects at risk. Recent large randomized clinical trials failed to document a benefit of a low dose folic acid administration in the clinical outcome of patients with atherosclerosis.

Purpose: As inflammation precedes atherosclerosis progression we sought to investigate the effects of high dose FA administration on inflammatory status in apolipoprotein E-deficient (apoE−/−) mice fed cholesterol-rich diet, an animal model of premature atherosclerosis

Methods: Apo E−/− mice were randomly assigned to four groups. The first group (n=9) was treated with regular diet (RD). The second group (n=18) was treated with RD and an aqueous solution of FA (75 mcg/kg/day). The third group (n=9) was treated with high-fat, high-cholesterol diet-western diet (WD). The fourth group (n=18) was treated with WD and FA for 6 weeks. Intereleukin (IL)-6, tumor necrosis factor alpha (TNFa) and regulated on activation, normal T cell expressed and secreted cytokine (RANTES) were measured with ELISA as well established inflammatory cytokines implicated in the progression of atherosclerosis.

Results: At the end of study period in mice fed with RD (group 1) FA treatment (group 2) decreased IL-6 levels [8.82 (3.51–35.37) pg/ml vs. 3.06 (1.42–3.552) pg/ml, p=0.01], while there was no impact in TNFa levels [2.30 (2.05–2.80) pg/ml vs. 2.10 (1.80–2.60) pg/ml, p=0.63] and in RANTES levels [12.25 (8.36–17.70) pg/ml vs. 9.80 (8.52–16.19) pg/ml, p=0.44]. In mice fed with WD (group 3), FA treatment (group 4) had no impact in IL-6 levels [4.93 (1.35–94.65) pg/ml vs. 20.25 (2.20–47.52) pg/ml, p=0.58], in TNFa levels [2.10 (1.70–5.89) pg/ml vs. 3.27 (2.50–4.32) pg/ml, p=0.17] and in RANTES levels [13.09 (10.43–30.42) pg/ml vs. 12.25 (5.90–29.88) pg/ml, p=0.69].

Conclusions: High dose folic acid administration in an atherosclerotic model of apoE deficient mice has only a modest anti-inflammatory effect and cannot reverse the additive atherosclerotic stimulus of a diet rich in cholesterol. These findings further elucidate the effects of folic acid administration in subjects with increased cardiovascular risk.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are